本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round led by Granite Asia. Founded in 2022, ChemLex develops AI technologies that radically accelerate chemical discovery for the pharmaceutical industry, significantly reducing time-to-market. In just three and a half years, it has grown to support more than 70 customers worldwide, including six of the world's top ten pharmaceutical companies. This surge reflects a larger industry shift as analysts expect the AI-powered drug discovery market to jump from USD 3.6B in 2024 to nearly USD 50B by 2034. At the core of ChemLex's platform is a 24/7 autonomous chemistry system that accelerates chemical discovery, making it far more cost-efficient and significantly more sustainable than traditional laboratory methods. Driving this is an innovative AI-powered, fully automated synthesis line, which runs experiments autonomously, captures data in real-time, and transforms chemical discovery from a stop-start process into a smooth workflow. The new funding will support the hiring of more hardware and software engineers, as well as chemists in Singapore, enabling the company to serve a broader pipeline of pharmaceutical and materials science projects. Sean Lin, Founder and CEO of ChemLex: "We're building an R&D engine that compresses months of synthesis and optimisation into weeks or even days, transforming both the speed and certainty of discovery. Singapore strengthens this effort and provides us an ecosystem to scale rapidly and support partners globally who need this capability now." Yinghui Kuang, Partner at Granite Asia: "AI-enabled chemistry is creating one of the most important industrial transitions of the decade, and ChemLex sits in that sweet spot, turning that shift into a business advantage with a platform that can accelerate molecule design and manufacturing at scale. This is the type of deeptech company that can reshape supply chains, shorten development timelines, and unlock new economic value, and Singapore gives them the foundation to grow." ChemLex also signed a memorandum of understanding with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development. This collaboration seeks to accelerate next-generation small molecule drug discovery through advanced automation. Prof. Damian O'Connell of the Experimental Drug Development Centre: "We first met ChemLex in 2023, and since then we've seen the company grow from a promising startup to a global innovator in AI and automation-driven chemical synthesis. As ChemLex's first Singapore partner, we are thrilled to expand our collaboration through the MOU. This partnership reinforces our shared vision of accelerating drug discovery and development through cutting-edge technology, ultimately bringing safer, more effective therapies to patients faster. By combining EDDC's drug development expertise with ChemLex's automation and AI capabilities, we aim to shorten timelines, reduce costs, and deliver innovative treatments that improve lives in Singapore and globally." These initiatives align with the Singapore Economic Development Board's (EDB) efforts to build a more resilient, innovation-ready life sciences ecosystem. Goh Wan Yee, Senior Vice President and Head, Healthcare, Economic Development Board: "ChemLex's decision to anchor its global R&D headquarters and AI laboratory in Singapore reflects how companies can leverage the confluence of our strengths in deep tech and biomedical sciences ecosystem, to launch breakthrough innovations. We look forward to supporting more like-minded partners like ChemLex, to accelerate scientific discoveries that will benefit patients worldwide."
MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC). The patient was dosed at the Australian Prostate Centre (APC) in Melbourne, Australia. ProstACT Global is the first Phase 3 trial to combine a PSMA[1]-targeted radio antibody-drug conjugate (rADC) therapy administered together with Standard of Care (SOC; abiraterone, enzalutamide or docetaxel) versus SOC alone. Part 2 of ProstACT Global will enroll approximately 490 patients and is currently recruiting patients in Australia, New Zealand and Canada. As previously agreed with FDA and disclosed to the market, Telix will submit Part 1 data to the United States (U.S.) Food and Drug Administration (FDA) to enable clearance to expand Part 2 of the trial to U.S. sites. A public disclosure of preliminary results from Part 1 of the study will be aligned to engagement with the FDA. The study is also approved to commence in China, Japan[2], Singapore, South Korea, Türkiye and the United Kingdom. As part of the further global expansion of the trial, Telix will file a clinical trial application (CTA) with the European Medicines Agency (EMA) to enable expansion into EU sites. Dr. David N. Cade, Group Chief Medical Officer, Telix, commented, "Dosing the first patient into Part 2 of the randomized treatment expansion of ProstACT Global trial is a significant milestone for Telix's late-stage prostate cancer therapeutics pipeline. We look forward to presenting the preliminary data from Part 1 of the study to the FDA and EMA in the coming months[3]." About ProstACT Global ProstACT Global (ClinicalTrials.gov ID: NCT06520345) is an international, multicenter trial in two parts: Part 1, safety and dosimetry lead-in with 30 patients (target enrollment complete); and Part 2, 2:1 randomized global expansion with an overall target enrollment of approximately 490 patients. Eligible patients must have confirmed progressive mCRPC assessed with a 68Ga-PSMA-11 PET[4] imaging agent (such as Illuccix® or Gozellix®, kits for the preparation of gallium-68 (68Ga) gozetotide injection) following prior treatment with an androgen receptor pathway inhibitor (ARPI). The antibody approach demonstrates different targeting and pharmacology to that observed in other PSMA-targeted small peptide radioligand therapies (RLT). In contrast to these therapies[5], collective long-term follow-up of patients administered with TLX591 has not observed significant acute or delayed kidney toxicity, as the agent is cleared through the liver, instead of the kidneys[6]. Due to its large molecular weight, TLX591 also demonstrates minimal salivary and lacrimal gland uptake, reducing dry mouth and dry eyes, common adverse effects of existing PSMA-targeted RLTs[7]. Additional information on the Phase 3 ProstACT Global study can be found at: https://telixpharma.com/prostact/ About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA[8]. TLX591 has not received a marketing authorization in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. [1] Prostate-specific membrane antigen. [2] Japanese regulator Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval for a Japan-specific Part 1 in nine patients, prior to commencing Part 2. [3] Collation of available published data. Not from head-to-head studies, cross trial or product data should be interpreted with caution. [4] Positron emission tomography. [5] Tagawa et al. Curr Oncol Rep. 2021; Steinhelfer et al. JNM. 2024. [6] Tagawa et al. Cancer. 2019. [7] Pepin et al. Pract Radiat Oncol. 2025. [8] Telix ASX disclosure 21 March 2025. Telix Investor Relations (Global)Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com Telix Investor Relations (U.S.) Annie Kasparian Telix Pharmaceuticals Limited Director Investor Relations and Corporate Communications Email: annie.kasparian@telixpharma.com Media ContactEliza Schleifstein917.763.8106 (Mobile)Eliza@schleifsteinpr.com This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2025 Telix Pharmaceuticals Limited. All rights reserved.
In the news release, "The 4th China International Supply Chain Expo Set for Beijing in June 2026", issued on Dec.7, 2025 by China International Supply Chain Expo over PR Newswire, we are advised by the company that there should be two photos with photo captions rather than just 1 photo without photo caption, as originally issued inadvertently. Complete, corrected release follows: The 4th China International Supply Chain Expo Set for Beijing in June 2026 Sustained Worldwide Outreach Drives Greater Collaboration Opportunities BEIJING, Dec. 7, 2025 /PRNewswire/ -- The 4th China International Supply Chain Expo ("CISCE," "the Expo") will be held in Beijing from June 22 to 26, 2026. To date, more than 300 companies have signed up to exhibit, with preparations moving forward smoothly. From November 30 to December 2, a delegation of Chinese business leaders organized by the China Council for the Promotion of International Trade (CCPIT) visited Canada, engaging in broad exchanges with government and industry representatives. At the Canada-China Forum on Trade and Investment Cooperation, the group gave a presentation on the upcoming Expo to over 150 government officials, institutional leaders, and corporate executives from both countries. Discussions centered on deepening collaboration in advanced manufacturing, digital technology, clean energy, and sustainable agriculture. Canada-China Forum on Trade and Investment Cooperation Held in Toronto，On-site Promotion the 4th China International Supply Chain Expo (CISCE). Following this, the CCPIT dispatched a delegation to the United States, engaging in extensive dialogues with American political and business leaders while conducting multiple promotional events across the country. On December 4, in Washington, D.C., CCPIT President Ren Hongbin addressed the forum "From Policy to Partnership: APEC 2026 – Unlocking Trade and Investment Potential." He noted the reciprocal benefits of U.S.-China commercial relations while reaffirming CCPIT's role in deepening practical cooperation and promoting the steady and long-term development of bilateral economic and trade ties. U.S. attendees showed considerable interest in strengthening supply chain ties with China. During the forum, the China International Exhibition Center Group delivered a dedicated presentation on the 4th CISCE. The Forum “From Policy to Partnership: APEC 2026 – Unlocking Trade and Investment Potential” Held in Washington, D.C. On-site Promotion the 4th China International Supply Chain Expo (CISCE) On December 5, the delegation attended the "Port of Opportunity: U.S.-China Business Networking Breakfast" in Oakland, California, focusing on digital technology, artificial intelligence, and other emerging sectors, to explore joint innovation opportunities within the two countries' industrial ecosystems. Another detailed presentation on the 4th CISCE was also shared. The Expo has become a vital platform for advancing international cooperation in global industrial and supply chains. The China Council for the Promotion of International Trade stated that it will continue to adhere to the strategic guidance of the 15th Five-Year Plan, ensuring high standards and superior quality in all preparations for the fourth edition of the Expo. Please visit https://en.cisce.org.cn/ for more up-to-date news about the 4th China International Supply Chain Expo.
北京2025年12月7日 /美通社/ -- 第四屆中國國際供應鏈促進博覽會（鏈博會）定於2026年6月22日至26日在北京舉行。截至目前，已有300余家企業簽約參展，各項籌備工作正穩步推進。 11月30日至12月2日，中國貿促會組織中國企業家代表團訪問加拿大，與加政商各界廣泛交流，並在中加貿易與投資合作論壇上推介第四屆鏈博會，邀請中加政府部門、機構和企業代表150余人圍繞先進制造、數字科技、清潔能源、綠色農業等重點合作領域開展交流洽談。 中加貿易與投資合作論壇在多倫多舉辦，現場推介第四屆鏈博會 隨後，中國貿促會組織代表團出訪美國，與美政界、工商界人士開展廣泛交流，並在美國進行多場推介。12月4日，「從政策到伙伴關系：APEC 2026——釋放貿易與投資潛能」論壇在華盛頓舉行。中國貿促會會長任鴻斌強調中美經貿互利共贏，中國貿促會將持續搭建高質量合作平台，支持中美企業深化務實合作，推動雙邊經貿關系行穩致遠。與會美國工商界代表對深化中美供應鏈合作表現出濃厚興趣。活動期間，中展集團就第四屆鏈博會進行了專題推介。 “從政策到伙伴關系：APEC 2026——釋放貿易與投資潛能”論壇在華盛頓舉辦，現場推介第四屆鏈博會 12月5日，代表團在奧克蘭出席「機遇之港：中美商業交流早餐會」。活動聚焦數字科技與人工智能等前沿領域，探討中美產業鏈協同創新的潛在機遇，並對第四屆鏈博會進行專題推介。 鏈博會已成為推動全球產業鏈供應鏈國際合作的重要平台。中國貿促會表示，將繼續以「十五五」規劃為戰略指引，高標准、高質量做好第四屆鏈博會各項籌備工作。
上海2025年12月7日 /美通社/ -- 12月4日至7日，組裝玩偶品牌布魯可(Blokees)首次亮相巴西聖保羅動漫展（Brazil Comic Con Experience，簡稱「CCXP」）。布魯可展出了其兩大產品線「布魯可拼裝模型」(Blokees Model Kits)與「布魯可輪式系列」(BLOKEES WHEELS)，展品近60款，全部是基於《變形金剛》(Transformers)、《侏羅紀世界》(Jurassic World)、《聖鬥士星矢》(Saint Seiya)、《新世紀福音戰士》(EVANGELION)等十餘個世界知名IP的產品。 在CCXP上，《聖鬥士星矢GALAXY VERSION 03黃金十二宮１》正式公佈並全球首發，回應了巴西市場的期待。這套新品包含9位角色，表情豐富，黃金聖衣細節精緻，生動再現了經典原作，激發了粉絲的共鳴與集齊十二位黃金聖鬥士的熱情。 《聖鬥士星矢》系列產品於2024年通過HERO 10和Champion系列由布魯可商業化。此次CCXP上，布魯可《聖鬥士星矢》Champion系列的三款灰模、三款塗裝完成品及兩款已發售模型首次正式公開亮相。憑借強大的研發實力和超過500項專利，布魯可已為HERO 10系列推出3個套裝，為Champion系列推出近十款角色，持續為《聖鬥士星矢》粉絲提供多樣化的產品與拼裝體驗。 此外，《變形金剛》等全球知名IP在巴西也擁有龐大且穩固的粉絲基礎。在CCXP展會上，布魯可近10款新品首次亮相，其中包括面向6至16歲消費者的變形金剛HERO 5系列和面向16歲以上消費者的Legend系列。 在CCXP展會上，布魯可還展出了「2025無畏賽季第三屆BFC創作大賽」(THE 3RD BFC CREATION CONTEST 2025 FEARLESS SEASON)的全球優秀作品，這是該賽季BFC作品首次線下展出，吸引了觀眾的目光。自「2025無畏賽季」起，BFC大賽正式從中國走向世界，已收到來自美國、英國、新加坡、印度尼西亞、馬來西亞等國愛好者提交的數百件作品，彰顯了BFC文化的全球影響力。 未來，布魯可將繼續發揮其強大的創新與研發能力，傳遞拼裝的樂趣。
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel, R&D code: CT053), has been included in China's Commercial Health Insurance Innovative Drug Catalogue (2025) (referred to as the "Innovative Drug Catalogue") for the treatment of relapsed/refractory multiple myeloma. The Innovative Drug Catalogue was released today at a press conference held by the National Healthcare Security Administration (NHSA) in Guangzhou. Dr. Huamao Wang, Co-founder and Chief Operating Officer of CARsgen, attended the conference. Zevor-Cel Included in China’s Commercial Health Insurance Innovative Drug Catalogue This year, the NHSA took the landmark step of establishing the Innovative Drug Catalogue, operating alongside the Basic Medical Insurance Catalogue. This Innovative Drug Catalogue specifically targets drugs that are highly innovative, of significant clinical value, and deliver substantial patient benefits. It is designed to empower the innovative drug industry chain with unprecedented support and enhance drug accessibility. Zevor-cel is a Category 1 innovative biological product with its Marketing Authorization (MA) held by CARsgen Life Sciences Co., Ltd., a subsidiary of CARsgen Therapeutics. It is manufactured by CARsgen Pharmaceuticals Co., Ltd. Zevor-cel was approved for marketing by the National Medical Products Administration (NMPA) on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have progressed after at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent). CARsgen has granted exclusive commercialization rights for zevor-cel in mainland China to Huadong Medicine Co., Ltd. (Stock Code: 000963.SZ). Huadong Medicine has established a dedicated, professional, and comprehensive commercial team to promote the use of zevor-cel and has been utilizing China's multi-layered insurance system to improve patient accessibility. Currently, certification and regulatory filings for zevor-cel have been completed in more than 20 provinces and municipalities across China. From January to September 2025, CARsgen received 170 confirmed orders from Huadong Medicine, exceeding the total number of orders for the full year of 2024. Five-year follow-up results from the Phase I clinical trial of zevor-cel, presented at the 2025 IMS Annual Meeting, demonstrated a manageable safety profile and deep, durable efficacy in patients with relapsed/refractory multiple myeloma. No grade 3 or higher cytokine release syndrome (CRS) was observed. No immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicities, second primary malignancy, or other delayed adverse events was observed. The overall response rate was 100% (95% CI: 76.8, 100.0) with 11 (78.6%) patients achieving complete response (CR) or stringent complete response (sCR). All patients who achieved CR or better were minimal residual disease (MRD) negative at 10⁻⁵ threshold. The median progression-free survival (mPFS) and the median duration of response (mDoR) were 44.1 months and 43.2 months in CR/sCR patients, respectively. The median overall survival (mOS) was not reached. The patient survival rate at 60 months post-infusion was 76.9%. Dr. Huamao Wang, Co-founder and Chief Operating Officer of CARsgen, said: "We are very pleased to see zevor-cel included in the first batch of the Innovative Drug Catalogue. This reflects the nation's high recognition of and policy support for innovative drugs. This inclusion will help further alleviate the financial burden on patients and enhance the accessibility of advanced cell therapies, allowing more patients to benefit from innovative treatments. CARsgen remains committed to addressing unmet clinical needs, developing more innovative and differentiated CAR T-cell products, bringing them to patients as quickly as possible, and contributing to the 'Healthy China' initiative." About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit https://www.carsgen.com/
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
